Introduction. Lung Cancer has been identified by the National Cancer Institute of the NIH as the leading cause of mortality among all cancers in the United States, with an estimated 155,870 deaths in 2017 alone. Non-small cell lung cancer (NSCLC) encompasses 85% of lung cancer diagnoses, and a normal pathway that is often mutated in most NSCLC cases is the Keap1/Nrf2 signaling pathway. Nrf2 is a transcription factor located within the cell cytoplasm that maintains reduction-oxidation homeostasis by regulating many protective enzymes, such as antioxidants, phase I and phase II detoxification enzymes, and drug efflux membrane transporters. Under homeostatic conditions, most Nrf2 is bound by Keap1, which is a negative regulator of Nrf2 activity. In tissue stains of tumors in patients with NSCLC, a common observation in the overexpression of Nrf2 and the under expression of Keap1. Further studies in Nrf2 knockout mice have shown that while Nrf2 functions to prevent the initiation of lung carcinogenesis, its overexpression paradoxically leads to the progression of lung cancer. Methods. A high-throughput screen was first used to screen out useful probe molecules out of 400,000 total molecules. The molecule identified that can bind to Nrf2 and inhibit it was ML385. Then clonogenic assays, treated with either doxorubicin or taxol, were created using ML385 and platinum-based drugs. Preclinical models of NSCLC cells with gain of Nrf2 function were used as targets of ML385 in combination with carboplatin. Statistical analyses were then conducted using a one-way ANOVA and post hoc test. Results. ML385 inhibits Nrf2 signaling in lung cancer cells and was shown to reduce Nrf2-mediated transcription and even reduce Nrf2 itself when administered against A549 cells. Interestingly, ML385 was also shown to be selectively toxic to the H460 NSCLC cell line with a point mutation in Keap1 but exert no effect on the growth of H460-Keap1 Knock-in H460 cells expressing wild-type Keap1. ML385 potentiated the toxicity of the chemotherapeutic drugs paclitaxel, doxorubicin, or carboplatin on H460 and A549 NSCLC cells with Keap1 mutations, leading to a reduction in tumor volume and weight. Conclusions. Targeting mutations in the Keap1/Nrf2 pathway is a necessary direction for the future of NSCLC treatments due to the variability and high mortality of this form of cancer. ML385 is a promising small molecule inhibitor of Nrf2 that should be used in combination with chemotherapeutic drugs to elicit the greatest reduction in NSCLC tumors.
- Acosta-Jimenez, Lourdes, Carey, et al. Aldo-keto reductases are biomarkers of NRF2 activity and are co-ordinately overexpressed in non-small cell lung cancer. Br J Cancer. 2016 Dec 6;115(12):1530-1539. doi: 10.1038/bjc.2016.363. Epub 2016 Nov 8.
- Biswal, Shyam, and JH Bloomberg School of Public Health. “Oxidative Stress, Metabolic Adaptation and Cancer Therapeutic Resistance.” Johns Hopkins Bloomberg School of Public Health. Johns Hopkins University, 31 Oct. 2016. Web. 15 May 2017. <http://www.jhsph.edu/departments/environmental-health-and-engineering/faculty/research/biswal/cancer.html>.
- “Cancer Stat Facts: Lung and Bronchus Cancer.” National Cancer Institute. NIH, n.d. Web. 20 May 2017. <https://seer.cancer.gov/statfacts/html/lungb.html>.
- Chen, J., Solomides, C., Simpkins, F. et al. The role of Nrf2 and ATF2 in resistance to platinum-based chemotherapy. Cancer Chemother Pharmacol (2017) 79: 369. doi:10.1007/s00280-016-3225-1
- Jeddi ,Farhad, Soozangar, Narges, et al. Contradictory roles of Nrf2/Keap1 signaling pathway in cancer prevention/promotion and chemoresistance, DNA Repair, Volume 54, June 2017, Pages 13-21, ISSN 1568-7864, http://doi.org/10.1016/j.dnarep.2017.03.008.
- Jeong Y, Hoang NT, Lovejoy A, et al. Role of keap1/nrf2 and tp53 mutations in lung squamous cell carcinoma development and radiation resistance. Cancer Discov. Epub 2016 Sep 23.
- Satoh, Hironori, Moriguchi, Takashi, et al. Nrf2 Prevents Initiation but Accelerates Progression through the Kras Signaling Pathway during Lung Carcinogenesis. Cancer Res July 1 2013 (73) (13) 4158-4168; DOI:1158/0008-5472.CAN-12-4499.
- Singh, Anju, Venkannagari ,Sreedhar, et al. Small Molecule Inhibitor of NRF2 Selectively Intervenes Therapeutic Resistance in KEAP1-Deficient NSCLC Tumors, ACS Chemical Biology 2016 11 (11), 3214-3225 DOI: 10.1021/acschembio.6b00651.
- Solis, Luisa M., Behrens, Carmen, et al. Nrf2 and Keap1 Abnormalities in Non–Small Cell Lung Carcinoma and Association with Clinicopathologic Features. Clin Cancer Res July 15 2010 (16) (14) 3743-3753; DOI: 10.1158/1078-0432.CCR-09-3352
- Penning Trevor, Aldo-Keto Reductase Regulation by the Nrf2 System: Implications for Stress Response, Chemotherapy Drug Resistance, and Carcinogenesis, Chemical Research in Toxicology 2017 30 (1), 162-176 DOI: 10.1021/acs.chemrestox.6b00319.
- Ryoo I, Lee S, Kwak M-K. Redox Modulating NRF2: A Potential Mediator of Cancer Stem Cell Resistance. Oxidative Medicine and Cellular Longevity. 2016;2016:2428153. doi:10.1155/2016/2428153.
- “What Is Small Cell Lung Cancer?” American Cancer Society. N.p., 16 May 2016. Web. 23 May 2017. <https://www.cancer.org/cancer/small-cell-lung-cancer/about/what-is-small-cell-lung-cancer.html>.